WPP backs outlook after expected decline in first quarter revenue
28th Apr 2026 10:37
(Alliance News) - WPP PLC on Tuesday reported lower revenue for the first quarter but reiterated its guidance for the full year. Read More
(Alliance News) - WPP PLC on Tuesday reported lower revenue for the first quarter but reiterated its guidance for the full year. Read More
(Alliance News) - Telecom Plus PLC on Tuesday warned that lower energy usage means that full-year profit will be at the low-end of prior guidance. Read More
(Alliance News) - Travis Perkins PLC on Tuesday said reduced construction activity is hurting sales volumes and sent revenue downward in the first three months of 2026. Read More
(Alliance News) - The following are the leading risers and fallers among FTSE 100 and 250 index constituents on Tuesday. Read More
(Alliance News) - The UK government has said it is "closely monitoring" UK jet fuel stocks as airlines prepare for a potential shortage. Read More
(Alliance News) - Santander UK has agreed to pay compensation for its portion of unfair motor finance deals. Read More
(Alliance News) - Coca-Cola Europacific Partners PLC on Tuesday backed full-year guidance after reporting first quarter sales growth amid "challenging" market conditions. Read More
(Alliance News) - Anglo American PLC on Tuesday reported a rise in copper, manganese and diamond output, but lower iron ore production in the first quarter, while subsidiary Kumba Iron Ore Ltd posted higher sales despite output falling. Read More
Ashoka India Equity Investment Trust PLC - invests in India-listed securities, as well as quoted companies with a significant presence in India - Director Jerome Booth sells 21,230 shares at 235.5 pence, worth GBP49,997, on Friday last week. Booth retains 64,292 shares. Read More
AstraZeneca PLC - Cambridge, England-based pharmaceutical maker - Breztri Aerosphere is approved by the US Food & Drug Administration as a maintenance treatment for asthma in patients 12 years and older. Breztri is a fixed-dose triple-combination therapy. It already was approved by the FDA in 2020 for the treatment of adults with chronic obstructive pulmonary disease. Astra says the new indication follows trials in which Breztri showed a "statistically significant and clinically meaningful improvement in lung function". Astra notes that Breztri is a maintenance therapy and isn't meant to replace a rescue inhaler to relieve sudden breathing problems. It says filings for Breztri in asthma are under review in the EU, Japan and China. Read More
(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and on Monday: Read More
(Alliance News) - Barclays PLC on Tuesday said it is confident delivering all its financial targets as it reported largely as expected first quarter results. Read More
GSK PLC - London-based pharmaceuticals maker - Bepirovirsen, GSK's treatment for chronic hepatitis B, is accepted for priority review and given 'breakthrough therapy designation' by the US Food & Drug Administration. GSK says the fast track approval process for its new drug application recognises bepirovirsen's potential for substantial improvement over existing treatments. Chronic hepatitis is a leading cause of liver cancer, and bepirovirsen, an investigational antisense oligonucleotide, showed "clinically meaningful functional cure rates" in phase III trials of adults. The FDA sets October 26 as its goal date for a decision on the drug application. Read More
(Alliance News) - Stock prices in London opened mixed on Tuesday, with gains among energy stocks offsetting weakness in banks and mid-caps. Read More
(Alliance News) - BP PLC on Tuesday announced better-than-expected first quarter profit reflecting "exceptional" oil trading results thanks to higher energy prices. Read More